NEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will participate in the upcoming 11
th
Annual LifeSci Partners Corporate Access virtual event and the H.C. Wainwright BioConnect Virtual Conference.
| Conference: |
11 th Annual LifeSci Partners Corporate Access virtual event |
| Format: | One-on-one virtual meetings |
| Dates: | January 5-7, 2022 |
| Register: |
https://www.meetmax.com/sched/event_78427/invitee_login.html |
| Conference: | H.C. Wainwright Global BioConnect Virtual Conference |
| Format: | On-demand recorded corporate presentation |
| Dates: | January 10, 2022 |
| Webcast: |
https://journey.ct.events/view/b30c9e23-05f3-4bc7-8e05-675b2cfa5a88 |
About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. In March 2021, Acer entered into a Collaboration and License Agreement with Relief for development and commercialization of ACER-001. For more information, visit
www.acertx.com
.
Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-430-7578
[email protected]
Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
[email protected]
